Delivery Strategies for Colchicine as a Critical Dose Drug: Reducing Toxicity and Enhancing Efficacy

Yaran Lei, Yulu Yang, Guobao Yang, Ao Li, Yuli Wang, Chunsheng GaoPharmaceutics 2024 · DOI

TL;DR

Colchicine, a potent anti-inflammatory drug, is limited by its narrow therapeutic window and severe gastrointestinal side effects. This review explores various delivery strategies—transdermal, injectable, and oral—aiming to reduce toxicity and enhance efficacy, with a particular focus on transdermal methods as a promising avenue.

What Problem Does This Paper Address?

Colchicine (COL) is a valuable natural compound with significant anti-inflammatory properties, used for conditions ranging from gout to cardiovascular diseases and even COVID-19. However, its clinical utility is severely hampered by a narrow therapeutic index, meaning the difference between an effective dose and a toxic dose is very small. The most common and significant adverse effects are gastrointestinal issues, which occur in a large percentage of patients. Current marketed formulations are primarily oral, which can lead to unpredictable absorption, peak-and-trough drug concentrations, and exacerbation of these side effects. This necessitates the development of alternative delivery strategies that can improve COL's safety profile and therapeutic effectiveness.

Methods

This paper is a review article, not an experimental study. It synthesizes existing research on different delivery strategies for colchicine. The authors categorize these strategies into three main routes:

  • Transdermal Drug Delivery: This is the primary focus. The review discusses various "permeation-promoting technologies" designed to help COL penetrate the skin's barrier. These include:
  • Pharmacological Permeation Promotion: Utilizing nanocarriers like liposomes (including elastomeric liposomes and ethosomes), lipid nanoparticles, cubosomes, and polymeric nanocarriers (e.g., chitosan nanoparticles).
  • Chemical Permeation Promotion: Employing chemical absorption enhancers like oleic acid and propylene glycol.
  • Physical Permeation Promotion: Using techniques such as microneedles.
  • Injectable Administration: This includes intravenous and intra-articular injections, often combined with nanocarrier systems for targeted delivery.
  • Oral Administration: The review discusses advancements in oral delivery, particularly sustained-release formulations like micropills, to manage the fluctuations seen with rapid-release tablets.

Datasets

Not discussed in the paper. This is a review article summarizing existing literature.

Key Insights and Ideas

  • Transdermal Delivery as a Game Changer: Transdermal delivery offers a compelling solution by bypassing the first-pass metabolism in the liver and avoiding direct gastrointestinal irritation, thereby significantly reducing toxicity.
  • The Skin Barrier Challenge: The skin's dense stratum corneum is a major hurdle for transdermal drug delivery, necessitating innovative permeation-promoting strategies.
  • Nanocarriers are Key Enablers: A wide array of nanocarrier systems (liposomes, nanoparticles, cubosomes, etc.) are being explored to encapsulate COL, improve its solubility, enhance skin penetration, and control its release.
  • Synergy is Crucial: Combining different approaches, such as nanocarriers with chemical enhancers or microneedles, shows promise for achieving superior transdermal delivery.
  • Targeted Injection for Specific Applications: Injectable routes, especially when coupled with targeted nanocarriers, are being developed for localized treatment (e.g., intra-articular injections for arthritis) or specific disease sites (e.g., colon cancer cells).
  • Oral Formulation Improvements: Even for oral delivery, moving from rapid-release to sustained-release formulations can significantly improve safety and efficacy by maintaining more stable drug concentrations.

Key Results

The paper does not present new experimental results but summarizes findings from various studies:

  • Transdermal Permeation: Studies show that elastomeric liposomes can increase COL permeation flux by 1.5-10.2 times compared to conventional liposomes or drug solutions. Microneedle arrays demonstrated a 3.36-fold higher drug penetration rate than COL gels.
  • Improved Bioavailability/Efficacy: Transdermal COL cubosomes showed 4.6 times higher bioavailability than oral solutions. Targeted nanocarriers for intravenous injection achieved up to 100% inhibition of colon cancer cells with reduced toxicity to normal cells. Intra-articular nanoemulsions prolonged drug retention in the joint cavity and improved anti-gout activity.
  • Reduced Toxicity: Transdermal routes inherently reduce gastrointestinal side effects. Targeted injectable systems also show reduced off-target cytotoxicity.

Limitations and Future Work

  • Limitations of Nanocarriers: Despite their promise, nanocarriers face challenges like low bioavailability, potential toxicity, immune responses, and difficulties in large-scale production. Polymeric nanocarriers have limited FDA approval due to aggregation and toxicity risks. Inorganic nanocarriers can be complex to synthesize, and their safety evaluation is still evolving.
  • Transdermal Challenges: Chemical enhancers can cause skin irritation, and microneedles raise concerns about invasiveness and infection risk. The long-term safety and toxicology of many nanocarrier-based transdermal systems require further investigation.
  • Future Directions:
    • More research is needed to develop effective COL delivery formulations, particularly for transdermal routes.
  • Systematic and in-depth studies on the dermal toxicology of inorganic nanomaterials are crucial.
  • Further investigation into the mechanism of permeation promotion by cubosomes is required.
  • The clinical translation of many nanocarrier technologies is still in its early stages, with most studies being laboratory-based. Future work should focus on bridging the gap from theory to practice and clinical application.
  • Addressing issues like particle aggregation, toxicity, immune responses, and cost-effectiveness for nanocarriers is essential.
  • More effective methods for coupling nanocarriers with chemical enhancers or microneedles need to be developed.

Summary updated

Abstract

Colchicine (COL), a widely used natural drug, has potent anti-inflammatory effects; however, as a narrow therapeutic index drug, its clinical application is limited by its serious gastrointestinal adverse effects, and only oral formulations are currently marketed worldwide. Recent studies have shown that transdermal, injection, and oral drug delivery are the three main delivery strategies for COL. This article elaborates on the research progress of different delivery strategies in terms of toxicity reduction and efficacy enhancement, depicting that the transdermal drug delivery route can avoid the first-pass effect and the traumatic pain associated with the oral and injection routes, respectively. Therefore, such a dosage form holds a significant promise that requires the development of further research to investigate effective COL delivery formulations. In addition, the permeation-promoting technologies utilized for transdermal drug delivery systems are briefly discussed. This article is expected to provide scientific ideas and theoretical guidance for future research and the exploration of COL delivery strategies.
BibTeX
@inproceedings{lei2024delivery,
  author = {Yaran Lei and Yulu Yang and Guobao Yang and Ao Li and Yang Yang and Yuli Wang and Chunsheng Gao},
  title = {{Delivery Strategies for Colchicine as a Critical Dose Drug: Reducing Toxicity and Enhancing Efficacy}},
  booktitle = {Pharmaceutics},
  year = {2024},
  doi = {10.3390/pharmaceutics16020222},
}
Figure